Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John J. Alam
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Beta
- -4.31
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.29
Financials
Revenue
$0.00-100.0%Net Income
$-6.57MEBITDA
$-6.57MFree Cash Flow
$-6.92MEPS (diluted)
$-0.64Shares Outstanding (diluted)
10.24M+111435.3%Operating Expenses
$6.68MCash & Debt
$24.94MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-26.97M | $-2.98 |
| 2024 | $0.00 | $-16.29M | $-2.02 |
| 2023 | $0.00 | $-2.17M | $-0.82 |
| 2022 | $0.00 | $-5.80M | $-11.20 |
| 2021 | $0.00 | $-24.10M | $-18.51 |
| 2020 | $0.00 | $-14.19M | $-22.50 |
| 2019 | $0.00 | $-11.80M | $-131.95 |
| 2018 | $0.00 | $-18.37M | $-424.93 |
| 2017 | $0.00 | $-1.36M | $-123.33 |
| 2016 | $0.00 | $-18.04M | $-1982.96 |
| 2015 | $0.00 | $-6.72M | $-28852.23 |
| 2014 | $0.00 | $-14.35M | $-11291.97 |
| 2013 | $71.7K | $-2.46M | $-11204.82 |
| 2012 | $374.5K | $-6.87M | $-93241.28 |
Valuation
CRVOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-50.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·8d ago·Negative
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 2…
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
CervoMed to Participate in September Investor Conferences BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:
View source ↗ - Newsglobenewswire.com·57d ago·Positive
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pur
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.61 per share
Typical surprise -11.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.64 vs $-0.87beat
- Mon, May 18$-0.86 vs $-0.90beat
- Fri, Mar 13$-0.88 vs $-0.79miss
- Fri, Nov 7$-0.84 vs $-0.68miss
- Fri, Aug 8$-0.70 vs $-0.61miss
- Mon, May 12$-0.56 vs $-0.60beat
Estimates and results for CRVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRVO officers and directors.
- Bought
- $10.0m
- Sold
- —
23 trades
1 trade
- Boger Joshua Sbought
- Boger Joshua Sbought
- Boger Joshua Sbought
- Winton Matthewbought
- Elder William Robertbought
- Winton Matthewbought
- Gregoire Sylviebought
- Gregoire Sylviebought
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CRVO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.